Raymond James Financial Inc. Takes $2.22 Million Position in Twist Bioscience Co. (NASDAQ:TWST)

Raymond James Financial Inc. purchased a new stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 47,863 shares of the company's stock, valued at approximately $2,224,000. Raymond James Financial Inc. owned about 0.08% of Twist Bioscience as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of TWST. Arizona State Retirement System boosted its holdings in Twist Bioscience by 1.3% during the 4th quarter. Arizona State Retirement System now owns 16,985 shares of the company's stock valued at $789,000 after acquiring an additional 219 shares during the period. Van ECK Associates Corp increased its stake in shares of Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after purchasing an additional 267 shares in the last quarter. Hillsdale Investment Management Inc. boosted its stake in Twist Bioscience by 0.4% in the 4th quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company's stock worth $3,625,000 after purchasing an additional 300 shares in the last quarter. US Bancorp DE lifted its position in Twist Bioscience by 72.0% in the 4th quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after acquiring an additional 601 shares in the last quarter. Finally, Blue Trust Inc. grew its stake in shares of Twist Bioscience by 19.9% in the fourth quarter. Blue Trust Inc. now owns 4,567 shares of the company's stock worth $206,000 after acquiring an additional 757 shares during the period.

Insiders Place Their Bets

In other news, CEO Emily M. Leproust sold 1,726 shares of the company's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $41.68, for a total value of $71,939.68. Following the sale, the chief executive officer now directly owns 660,966 shares in the company, valued at approximately $27,549,062.88. This represents a 0.26 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Patrick John Finn sold 2,058 shares of the firm's stock in a transaction that occurred on Wednesday, April 23rd. The stock was sold at an average price of $39.99, for a total transaction of $82,299.42. Following the sale, the chief operating officer now directly owns 265,460 shares of the company's stock, valued at approximately $10,615,745.40. The trade was a 0.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 12,137 shares of company stock worth $530,112 in the last quarter. 3.01% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Robert W. Baird lifted their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research note on Tuesday, February 4th. Barclays decreased their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Guggenheim set a $50.00 price target on Twist Bioscience in a research report on Friday, March 28th. JPMorgan Chase & Co. lifted their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research note on Tuesday, February 4th. Finally, Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Twist Bioscience has an average rating of "Moderate Buy" and a consensus price target of $52.80.

Twist Bioscience Stock Performance

NASDAQ:TWST traded down $2.23 during trading hours on Monday, reaching $37.02. 1,325,276 shares of the stock were exchanged, compared to its average volume of 968,477. The stock has a market capitalization of $2.21 billion, a P/E ratio of -10.92 and a beta of 2.54. Twist Bioscience Co. has a 52 week low of $33.16 and a 52 week high of $60.90. The firm has a 50 day simple moving average of $39.24 and a 200-day simple moving average of $44.06. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. The business had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business's quarterly revenue was up 24.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.75) earnings per share. As a group, sell-side analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.